An Australian, who moved to the US in 1987, John grew a start-up to a billion-dollar public company with 3500+ employees. He sponsored and co-founded the New Jersey Technology Council, now with 1500 entrepreneurs as members, which is aimed at creating an exchange for entrepreneurs’ experiences and ideas. John has personally invested in 14 early stage US companies and 5 in the UK and has been involved and co-invested in several turnarounds for US Private Equity Funds.
John is best known as a healthcare information technology specialist having founded and then grown the world’s first sales force automation system which was focused on healthcare industries. Dendrite grew to serve 52 countries, had 26 international offices, was public for 15 years (Nasdaq) and employed over 3,500 people. It was valued on sale at over $800m.
While Chairman and CEO, John was responsible for 22 acquisitions both large and small but is most proud of the fact that Dendrite as an organisation created a reputed 38 millionaires and 18 multimillionaires through the hard work of its talented people, and over 30 new businesses have also been founded by Dendrite Alumni.
John was subsequently appointed by investors to be the Chairman and CEO of EKR Therapeutics, a specialist hospital products provider which manufactured and sold high technology Biologics among other products. John was involved with the turnaround and strategic development process, which led to the sale of the company within 3 years for a 3.8x return to investors.
Since arriving in the UK three years ago, John has already invested in five UK businesses